Valuation : Indivior Pharmaceuticals, Inc.

Market Cap 4.23B 3.63B 3.41B 3.11B 5.87B 403B 5.9B 40.31B 15.62B 203B 15.87B 15.53B 674B P/E 2026 *
9.63x
P/E 2027 * 8.73x
Enterprise Value 4.22B 3.62B 3.4B 3.1B 5.85B 402B 5.88B 40.19B 15.57B 203B 15.83B 15.48B 672B EV / Sales 2026 *
3.16x
EV / Sales 2027 * 2.61x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.23B
-3.59%-7.10%+61.60%+114.83% 1,060B
-1.15%-1.25%+52.98%+62.41% 651B
-1.09%-1.15%+26.18%+79.22% 465B
-0.72%-1.61%+39.30%+41.15% 365B
-1.07%-0.27%+23.55%+39.29% 300B
-0.55%+1.18%+2.70%+12.85% 258B
-0.43%-0.46%+52.06%+71.75% 238B
-2.67%+0.32%-16.71%-54.04% 210B
-0.46%+0.33%+29.05%+92.67% 184B
Average -0.86%-0.66%+32.02%+43.99% 414.49B
Weighted average by Cap. -0.69%-2.16%+39.76%+67.46%

Financials

2026 *2027 *
Net sales 1.33B 1.14B 1.07B 980M 1.85B 127B 1.86B 12.7B 4.92B 64.09B 5B 4.89B 212B 1.4B 1.2B 1.13B 1.03B 1.94B 133B 1.95B 13.34B 5.17B 67.34B 5.25B 5.14B 223B
Net income 474M 407M 382M 349M 659M 45.23B 662M 4.52B 1.75B 22.82B 1.78B 1.74B 75.58B 530M 455M 427M 390M 736M 50.55B 739M 5.05B 1.96B 25.5B 1.99B 1.95B 84.46B
Net Debt -12.5M -10.73M -10.07M -9.2M -17.36M -1.19B -17.44M -119M -46.18M -601M -46.93M -45.92M -1.99B -570M -489M -459M -419M -792M -54.37B -795M -5.43B -2.11B -27.43B -2.14B -2.09B -90.84B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
35.82USD
Average target price
49.00USD
Spread / Average Target
+36.78%

Quarterly revenue - Rate of surprise